Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis
Key facts
- Who runs it
- Mount Sinai Hospital, Canada
- Where
- Dayton, Phoenix, and San Antonio, United StatesSee the 3 sitesAlso in 4 other countries, 19 sites
- Trial code
- Status
- Recruiting
- People taking part
- 550 people, planned
- Started
- 6 Feb 2023
- Expected to end
- 31 Mar 2028
- Type of study
- Observational, 2 groups
- Treatments tested
- Dopamine
- Norepinephrine
- Record updated
- 16 October 2026
Who can take part
- Age
- 21 weeks to 32 weeks
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- ≤32 weeks gestational age and > 48 hours of life
- Receiving primary vasopressor therapy with Dopamine or Norepinephrine in the context of suspected late-onset sepsis or necrotizing enterocolitis with systemic hypotension (defined as: culture positive or negative bloodstream infection)
Who cannot take part
- Receiving primary therapy with agents other than Dopamine or Norepinephrine
- Known chromosomal or genetic anomalies
Where in United States
Also in 4 other countries, 19 sites
- Dayton Children's HospitalDayton, United StatesContact: Shreyas AryaTaking people
- Banner-University Medical Center PhoenixPhoenix, United StatesContact: Suma RaoNot yet recruiting
- Methodist HealthcareSan Antonio, United StatesContact: Melissa Althouse, MDTaking people
About the trial
What the trial wants to find out
Fluid-unresponsive hypotension needing cardiotropic drug treatment is a serious complication in very preterm neonates with suspected late-onset sepsis (LOS; defined as culture positive or negative bloodstream infection or necrotizing enterocolitis occurring >48 hours of age). In Canada, ~250 very preterm neonates receive cardiotropic drugs for LOS related fluid-unresponsive hypotension every year; of these ~35-40% die. Unlike for adult patients, there is little evidence to inform practice. While several medications are used by clinicians, the most frequently used medications are Dopamine (DA) and Norepinephrine (NE). However, their relative impact on patient outcomes and safety is not known resulting in significant uncertainty and inter- and intra-unit variability in practice. Conducting large randomized trials in this subpopulation can be operationally challenging and expensive. Comparative effectiveness research (CER), is a feasible alternative which can generate high-quality real-world evidence using real-world data, by comparing the impact of different clinical practices.
Read full original descriptionShow less
Aim: To conduct an international CER study, using a pragmatic clinical trial design, in conjunction with the existing infrastructure of the Canadian Neonatal Network to identify the optimal management of hypotension in very preterm neonates with suspected LOS.
Objective: To compare the relative effectiveness and safety of pharmacologically equivalent dosages of DA versus NE for primary pharmacotherapy for fluid-unresponsive hypotension in preterm infants born ≤ 32 weeks gestational age with suspected LOS.
Hypothesis: Primary treatment with NE will be associated with a lower mortality
Methods: This CER project will compare management approach at the unit-level allowing inclusion of all eligible patients admitted during the study period. 16 centers in Canada, 2 centers in Ireland, 1 center in each of Israel, Spain and the UK, and 6 centers in the United States have agreed to standardize their practice. All eligible patients deemed circulatory insufficient will receive fluid therapy (minimum 10-20 cc/kg). If hypotension remains unresolved:
Dopamine Units: start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response
Norepinephrine Units: start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response
The 2 groups in the trial
- Dopamine Units
Units who have standardized their practice with the use of Dopamine as a first line agent.
Treatment: Dopamine
- Norepinephrine Units
Units who have standardized their practice with the use of Norepinephrine as a first line agent.
Treatment: Norepinephrine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Dopamine vs. Norepinephrine for Hypotension in Very Preterm Infants With Late-onset Sepsis: An International Comparative Effectiveness Research Project
- Record updated
- 16 October 2026